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Abstract
Recent findings indicate that fingolimod, the first oral drug approved for the
treatment of multiple sclerosis (MS), acts as a direct inhibitor of histone deacety-
lases (HDACs) and enhances the production of brain-derived neurotrophic fac-
tor (BDNF) in the CNS. Both mechanisms are relevant to the pathophysiology
and treatment of major depression. We examined the antidepressant activity of
fingolimod in mice subjected to chronic unpredictable stress (CUS), a model of
reactive depression endowed with face and pharmacological validity. Chronic
treatment with fingolimod (3 mg kg1, i.p., once a day for 4 weeks) reduced the
immobility time in the forced swim test (FST) in a large proportion of CUS
mice. This treatment also caused anxiogenic-like effects in the social interaction
test without affecting anxiety-like behavior in the elevated plus maze or spatial
learning in the water maze. CUS mice showed reduced BDNF levels and
enhanced HDAC2 levels in the hippocampus. These changes were reversed by
fingolimod exclusively in mice that showed a behavioral response to the drug in
the FST. Fingolimod treatment also enhanced H3 histone K14-acetylation and
adult neurogenesis in the hippocampus of CUS mice. Fingolimod did not affect
most of the parameters we have tested in unstressed control mice. The antide-
pressant-like activity of fingolimod was confirmed in mice chronically treated
with corticosterone. These findings show for the first time that fingolimod exerts
antidepressant-like effect acting in a “disease-dependent” manner, and raise the
interesting possibility that the drug could relieve depressive symptoms in MS
patients independently of its disease-modifying effect on MS.
Abbreviations
BDNF, brain-derived neurotrophic factor; BrdU, 5-Br-20-deoxyuridine; CUS,
chronic unpredictable stress; DCX, doublecortin; EPM, elevated plus maze; FST,
forced swim test; H3K14Ac, H3 histone acetylated on Lys14; HDAC, histone de-
acetylase; MS, multiple sclerosis; MWM, morris water maze; S1PR, sphingosine-1-
phosphate receptor; SI, social interest; SPT, sucrose preference test; SR, social rec-
ognition.
Introduction
Multiple sclerosis (MS) is an immune-mediated disease
that affects the white matter of the CNS and causes
demyelination, axonal degeneration, and neuronal death.
Optic neuritis, pyramidal tract symptoms, and cerebellar
dysfunction are hallmark features of MS. However, psy-
chiatric symptoms such as depressed mood, anhedonia,
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anxiety, and sleep disturbances may be present, and
sometimes match the criteria for a comorbid diagnosis
(Compston and Coles 2008).
Depression shows a high prevalence (up to 50%) in
MS patients, and may worsen the course of MS by reduc-
ing the compliance to medication (D’Alisa et al. 2006;
Feinstein 2007, 2011; Minden et al. 2014). Depression
might develop in MS patients as a result of neuroinflam-
mation or axonal damage in brain circuits involved in
mood control (Miller et al. 2009; McNamara and Lotrich
2012; Felger and Lotrich 2013), or, more simply, might
be a consequence of the poor quality of life and the
awareness of a progressive neurological impairment in
MS patients. In addition, interferon-b (IFN-b), which is a
first-line drug in the treatment of MS, may cause depres-
sion de novo or worsen preexisting depression (Patten
et al. 2005).
Most disease-modifying drugs used in the treatment of
MS act preferentially outside the CNS to restrain autoim-
munity (Comi 2013). Fingolimod, the first oral drug
approved for the treatment of relapsing-remitting MS,
causes immune suppression by inhibiting the egress of
certain populations of T lymphocytes from secondary
lymphoid organs (Aktas et al. 2010; Brinkmann et al.
2010; Pelletier and Hafler 2012). However, a growing
body of evidence suggests that fingolimod may also act
on neurons and glial cells resident in the CNS (Brink-
mann et al. 2010; Pelletier and Hafler 2012; di Nuzzo
et al. 2014). Fingolimod is a highly lipophilic sphingosine
analog, which is transformed into the active metabolite,
fingolimod-P, by intracellular type-2 sphingosine kinase.
Fingolimod-P activates four types of membrane sphingo-
sine-1-phosphate receptors (S1PR1, -3, -4, and -5), acting
as a “superagonist” of S1P1R. Overactivation of S1P1R
causes receptor internalization resulting into functional
antagonism (Brinkmann et al. 2010).
Recent data indicate that fingolimod-P may also act in
the cell nucleus to stimulate histone acetylation and gene
expression via a direct inhibition of class-I histone deacet-
ylases (HDACs) (Hait et al. 2014). This epigenetic mecha-
nism provides a potential link between fingolimod and
depression because HDAC inhibitors are known to pro-
duce antidepressant-like effects (Sun et al. 2013), and
chronic social defeat stress causes a persistent decrease in
H3 histone K14-acetylation (H3K14Ac) in the hippocam-
pus (Covington et al. 2011).
Another link with depression is the ability of fingoli-
mod to enhance the production of brain-derived neuro-
trophic factor (BDNF) in neurons (Deogracias et al. 2012;
Doi et al. 2013; Fukumoto et al. 2014; Hait et al. 2014).
BDNF levels are reduced in the hippocampus of mice
exposed to acute or chronic stress (Nibuya et al. 1995;
Barrientos et al. 2003), and in the hippocampus and
peripheral blood of depressed patients (Shimizu et al.
2003; Karege et al. 2005; Sen et al. 2008). In addition, an
impairment of BDNF signaling in the hippocampus
results into a depressive-like phenotype (Monteggia 2007;
Taliaz et al. 2010), whereas increases in hippocampal
BDNF levels cause antidepressant-like effect (Shirayama
et al. 2002; Hoshaw et al. 2005; Krishnan and Nestler
2010).
From a therapeutic standpoint, it would be important
to examine the antidepressant-like effect of fingolimod in
mice developing experimental autoimmune encephalomy-
elitis (EAE), which models MS. However, this is an
impossible task because the severe motor impairment
associated with EAE precludes the analysis of depressive-
like behavior. Thus, we decided to test the antidepressant-
like activity of fingolimod using mice exposed to chronic
unpredictable stress (CUS), which models reactive depres-
sion. We also examined the action of fingolimod in a sec-
ond mouse model of depression based on chronic
systemic treatment with corticosterone.
Materials and Methods
Animals and drugs
Six-week old C57BL/6J male mice were purchased from
Harlan Laboratories (Italy). Animals were housed four
per cage under standard conditions, with access to food
and water ad libitum and a 12 h light/dark cycle (light on
at 07:00 AM). Experimental procedures were carried out
according to the European (86/609/EEC) and Italian (D.
Lgs 116/92) guidelines of animal care. All efforts were
made to minimize the number of animals used and their
suffering. The experimental protocol was approved by the
Italian Ministry of Health. Fingolimod hydrochloride (2-
amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol, hydro-
chloride) was purchased by CABRU (Arcore, Italy), and
dissolved in saline. Corticosterone was purchased from
Sigma Aldrich (Milano, Italy).
Experimental design
We have tested the antidepressant-like activity of fingoli-
mod using two established models of depression in mice:
(i) exposure to CUS; and (ii) chronic administration of
corticosterone. In the CUS paradigm, we used two sets of
mice, each including the following groups: (i) unstressed
mice treated i.p. with saline or fingolimod (3 mg kg1)
for 4 weeks; and (ii) mice exposed to CUS daily for
4 weeks and chronically treated with saline or fingolimod
(see above) starting after 3 weeks of CUS. The first set of
mice (Fig. 1A) was used for the assessment of depressive-
like behavior in the forced swim test (FST) prior to the
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onset of CUS, at the end of the third week of CUS, and
then 30 min after the last administration of saline or fin-
golimod. The sucrose preference test (SPT) was per-
formed at baseline and after 3 weeks of CUS, 1 h after
the FST. Mice were killed 24 h after the last FST session
for biochemical analysis.
The second set of mice (Fig. 4A) was used for a battery
of behavioral tests including the elevated plus maze
(EPM, performed prior to the onset of CUS and 12 h
after the last administration of saline or fingolimod), the
“single-day” Morris water maze (MWM) (performed
3 days after the end of treatments), and the social interac-
tion test (performed 4 days after the MWM). At the end
of the last behavioral session, all mice were treated with
5-bromo-20-deoxyuridine (BrdU; Sigma Aldrich) and
killed after 2 days for the assessment of hippocampal neu-
rogenesis.
In the corticosterone model, mice were injected s.c. once
daily for 21 days with either vehicle (1% Dimethyl sulfox-
ide (DMSO) in saline solution) or 20 mg kg1 of cortico-
sterone. Corticosterone was initially dissolved in DMSO
(100 mg mL1), and then diluted 1:100 into saline. The
injection volume was 400 lL. Mice that had received cor-
ticosterone were treated i.p. for 4 additional weeks with
saline or fingolimod (3 mg kg1). Mice that had received
the vehicle alone, were exclusively treated with saline. The
FST and SPT were carried out with the sequence described
above at baseline, at 3 weeks (at the end of treatment with
corticosterone or vehicle), and at 7 weeks (at the end of
treatment with fingolimod or saline).
Chronic stress procedure
Mice were subjected to various unpredictable stressors for
28 days. For the first 21 days of stress, we used a modi-
fied version of the CUS protocol described by Koo et al.
(2010). The stress protocol consisted of 1–3 h sessions in
the morning and an overnight session (Table 1). The fol-
lowing stressors were delivered in the first 3 weeks: food
deprivation for 12 h; 45° cage tilt for 12 h; wet bedding
(250 mL of water in 750 mL of bedding) for 12 h; over-
night illumination; 1-h restraint stress in a 15 9 5-cm
cylinder; cage rotation for 1 h; different partner for 3 h;
strobe light exposure overnight; overcrowding for 12 h;
and light off for 3 h. During the last week of stress, the
following items were intensified to avoid habituation or
coping strategies: (i) 12 9 3 cm plastic tubes with tip cut
off to allow breathing were used for restraint stress; (i)
wet bedding and cage rotation were combined for 3 h;
and (iii) the light–dark cycle was reversed during the last
weekend. In experiment #1, the CUS procedure was inter-
rupted for 24 h after day 21. During this time, mice were
subjected to FST, and then caged individually for 20 h for
the assessment of sucrose preference. There was no inter-
ruption of the CUS procedure experiment #2. Control
mice were not exposed to stress and were maintained
undisturbed in their home cages.
FST
The FST (Porsolt et al. 2001) was performed in the morn-
ing (from 8 to 11 AM). Mice were allowed to adapt to the
experimental room 1 h before testing. The third FST ses-
sion (at the end of treatments) was performed 30 min after
the injection of saline or fingolimod. Two mice were placed
simultaneously in individual side-by-side Plexiglas cylin-
ders (13 cm diameter 9 24 cm high) containing 15 cm of
water at 22–23°C, separated by an opaque screen. Mice
were videotaped, and the immobility time was calculated in
the last 4 min of the 6-min session. A mouse was judged
immobile when it stopped all movements except those nec-
essary to keep its head above the water.
SPT
The SPT was performed for 20 h starting at 12 PM (i.e.,
1 h after the end of the FST). Mice were caged individu-
ally with free access to two different drinking bottles, the
first containing water and the other filled with a 2%
sucrose solution. The position of the two bottles was
switched after 10 h from the beginning of the test, in
order to avoid any side preference in drinking behavior.
CUS mice had not been exposed to food or water depri-
vation for several days prior to the SPT (see Table 1).
The preference for sucrose solution was assessed by
weighing the bottles and calculated as a percentage of
total fluid consumption.
EPM
The EPM was used as a test of anxiety (Rodgers and Dal-
vi 1997). The test was performed for the first time after
3 days of habituation to the experimenters. The maze,
placed in a completely dark room, is a cross-shaped appa-
ratus elevated 50 cm from the floor with two opposed
open arms (5 9 30 cm), two closed arms (5 9 30 9
20 cm), and an open central zone (5 9 5 cm). Mice were
put in the central zone with the head in the direction of
one of the open arms and left free to move on the appa-
ratus for 5 min. No training was performed, therefore,
the animal’s behavior was spontaneous and uncondi-
tioned. Measurements of the time spent and the number
of entries in both open and closed arms were considered
as measures of locomotor and exploratory activity. The
performance of all animals was videotaped with a camera
mounted above the maze and the videos were then ana-
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lyzed with the EthovisionXT software (Ethovision 8.5;
Noldus Information Technology, Wageningen, The Neth-
erlands).
MWM
We adopted a modified protocol of the MWM using a
circular pool with a diameter of 100 cm and a height of
34 cm, filled with 20  1°C water to a depth of 25 cm,
with nonreflective interior surfaces, was placed in a com-
pletely dark room. The maze was divided into four equal
quadrants and release points were assigned at quadrants
NW, SW, and SE. A hidden circular platform (11 cm in
diameter), was located in the center of the NE quadrant,
submerged 1.5 cm beneath the surface of the water. A
nontoxic paint was used to make the water white. Two
(A)
(B)
(D)
(C)
(E)
(F) (G)
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fixed, visual cues were present at various locations (NE
and SW) around the maze. The task required mice to
swim to the hidden platform guided by distal cues. Mice
were subjected to three blocks of three trials each, with
an interblock interval of at least 30 min, during which
animals were returned to their home cage. Three different
starting positions were equally distributed around the
perimeter of the maze and randomized within each block.
After mounting the platform, mice were allowed to
remain there for 10 sec until the start of the next trial.
The animals were given a maximum of 90 sec to find the
platform; if they failed to find the platform in this time,
they were placed by the experimenter on the platform
and allowed to stay there for 10 sec. After completion of
each block of trials, animals were returned to their home
cage. One hour after the end of the three blocks, an extra
90-sec trial (probe trial) was performed. During probe
trial, the platform was removed and the time spent by
animals in each quadrant was recorded. A camera was
mounted above the center of the maze and automated
tracking was performed using the EthovisionXT software
(Ethovision 8.5, Noldus Information Technology). For all
the trials, both the time spent to find the platform and
the total distance were measured. The time spent in each
quadrant and in the circular zone of platform and near
platform was recorded during the probe trial.
Social interaction test
The apparatus, placed in a totally dark room, consisted of
a three-chamber plexiglass box with a nonreflective white
floor and walls (outer: 60 9 40 9 22 cm; chambers:
20 9 40 9 22 cm). Rectangular openings (5 9 8 cm)
were located on the inner dividing walls, so that mice
were free to move across all the chambers of the box.
Two cylindrical cages (internal diameter: 7 cm; height:
17 cm) with metal mesh walls and two white plastic caps
were positioned in the distant corner of the outer cham-
bers. Animals were habituated to the apparatus for
10 min, 2 days before the test. Testing consisted of three
consecutive trials: habituation/acclimation to the environ-
ment, social interest (SI), and social recognition (SR).
Habituation lasted for 5 min, while SI and SR lasted for
3 min; each step was delayed for 5 min, and during
Table 1. Chronic stress protocol.
Days of stress Stressor Duration Modifications during week 4
1, 8, 11, 24 Food deprivation Overnight Food and water deprivation
1, 2, 9, 13, 20, 22, 25 Cage rotation 1 h Cage rotation for 3 h
2, 7, 9, 13, 20, 26 Light on Overnight Inversion of light/dark cycle (day 26)
4, 7, 11, 15, 17, 26, 28 Light off 3 h Inversion of light/dark cycle (day 26)
5, 8, 12, 19, 21, 23, 24 Different partner 3 h In overcrowding
3, 14, 16, 19, 21, 23, 25 Cage tilt Overnight In overcrowding
3, 6, 10, 14, 16, 18, 27 Restraint 1 h Restraint in 50-mL plastic tubes
6, 10, 17, 27 Strobe Overnight In overcrowding
5, 12, 15, 18, 28 Wet bedding Overnight In overcrowding
Figure 1. Antidepressant-like activity of Fingolimod in mice exposed to chronic unpredictable stress (CUS). The design of experiment #1 is shown
in (A). Mice were exposed to CUS for 4 weeks, with 1 day of interval after the end of the third week for the analysis depressive-like behavior in
the forced swim test (FST) and sucrose preference test (SPT). A four-week treatment with saline or Fingolimod (3 mg kg1, once daily) was
started at the beginning of the 4th week of CUS. Mice were killed 1 day after the last FST. Cumulative data of the FST in all unstressed and CUS
(stressed) mice (n = 21 and 38, respectively) is shown in (B), where data (means + SEM) are expressed as the difference of immobility time (D)
between values obtained at week 3 and time 0. *P < 0.05 (Student’s t-test; t(57) = 3.53) versus unstressed mice. Mice resilient (n = 13) and
nonresilient (n = 25) to stress are shown in (C), where the cutoff value for resilience was considered <1 Standard Deviation Score (SDS) with
respect to the mean value of immobility time in unstressed mice. SDS = (x  l)/r, where x = the immobility time of each CUS mouse; l and
r = mean and SD of the immobility time in unstressed mice. The overall effect of Fingolimod on the immobility time in the FST is shown in (D),
where data (means + SEM) are expressed as the difference of immobility time (D) between values obtained at week 7 and week 3. *P < 0.05
(Student’s t test; t(20) = 2.62) versus mice treated with saline (n = 9 and 13 mice treated with saline and Fingolimod, respectively). Mice
responsive and not responsive to the antidepressant-like activity of Fingolimod are shown in (E), where the cutoff for drug response was
considered ≤1 SDS with respect to the mean value of immobility time in CUS mice treated with saline. Absolute values of immobility time in
nonresilient CUS mice treated with saline (n = 9) or Fingolimod (n = 13, divided into nine responders and four nonresponders) are shown in (F),
where values are means + SEM. One-way ANOVA + Tukey’s t-test; F(2,19) = 12.86; P < 0.05; post hoc analysis: (*) P < 0.05 versus all other
values. In (G), data obtained in responders and nonresponders to Fingolimod were combined and compared to data obtained in mice treated
with saline. *P < 0.05 (Student’s t-test; t19 = 2.141).
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intervals animals were put in their home cage. For each
trial, mice were initially positioned in the central chamber
and then were left free to explore the apparatus. During
the SI trial, mice were exposed to a “familiar” conspecific
placed in one of the two metal cages, while the other cage
remained empty. During the SR trial, the “familiar” con-
specific was left in the same cage, and in the empty one a
“novel” conspecific was placed. The cage of the “familiar”
conspecific was left in the same position during the SR
trial. Conspecifics were habituated to stay in the metal
cages inside the box for 5 min in the 2 days preceding
the test day. Animal behavior in all trials was video-
recorded and time spent in exploration of three chambers
and of the metal cages was analyzed and calculated with
the EthovisionXT software (Ethovision 8.5, Noldus
Information Technology).
Immunostaining and stereological counting
of BrdU- or DCX-expressing cells in the
dentate gyrus
For immunohistochemical analysis of cells expressing
BrdU and doublecortin (DCX), brains were fixed in Car-
noy’s (ethanol: acetic acid: chloroform, 6:1.3), embedded
in paraffin, and sectioned at 20 lm. Deparaffinized sec-
tions were soaked in 3% hydrogen peroxide to block
endogenous peroxidase activity. Sections were treated
with 10-mmol/L citrate buffer (pH 6.0), and heated in a
microwave for 10 min for antigen retrieval. The slides
were allowed to cool for 20 min in the same solution at
room temperature and then washed in TBS (Tris-buffered
saline). The sections were incubated overnight with
mouse monoclonal anti-BrdU (1:10, Becton Dickinson,
Franklin Lakes, NJ, USA) or goat polyclonal anti-DCX
(1:20, Santa Cruz Biotechnology Inc., Dallas, Texas,
U.S.A.) antibodies, and then for 1 h with secondary bioti-
nylated anti-mouse or anti-rabbit antibodies (1:200; Vec-
tor Laboratories, Burlingame, CA). 3,3-Diaminobenzidine
tetrachloride was used for detection (ABC Elite kit; Vec-
tor Laboratories). Control staining was performed with-
out the primary antibodies.
The number of DCX+ neurons or BrdU+ cells in the
dentate gyrus of the hippocampus was assessed by stereol-
ogical technique and an optical fractionator using a Zeiss
Axio Imager M1 microscope (Carl Zeiss Microscopy,
Thomwood, NY, U.S.A.) equipped with a motorized stage
and focus control system (Zeta axis), and with a digital
video camera. The software Image-Pro Plus 6.2 for Win-
dows (Media Cybernetics, Inc., Bethesda, MD) equipped
with a Macro was used for the analysis of digital images.
The Macro was obtained by Immagine and Computer,
Bareggio, Italy and the characteristics of this Macro are
published (King et al. 2002). The analysis was performed
on eight sections of 20 lm (for either BrdU or DCX
staining), sampled every 200 lm on the rostro-caudal
extension of the hippocampus, in which the dentate gyrus
was identified and outlined at 2.59 magnification. DCX
or BrdU-positive cells were counted at 1009 magnifica-
tion, with 1.3 as numerical aperture of the lens, as
described (Gundersen and Jensen 1987). For stereological
analysis, we used a grid of disectors with these character-
istics: counting frame of 60 9 60 lm; grid size
150 9 150 lm. The total number of DCX-positive cells
per dentate gyrus was computed from the formula:
N = Σ(n) 9 1/SSF 9 1/ASF 9 1/TSF, where n is the
total number of cells counted on each disector; SSF (frac-
tion of sections sampled) the number of regularly spaced
sections used for counts divided by the total number of
sections across the striatum (= 1/8); ASF (area sampling
frequency) the disector area divided by the area between
dissectors (3600 lm2 9 disector number/region area);
and TSF (thickness sampling frequency) the disector
thickness divided by the section thickness (19/20 lm).
Western blot analysis
Mice were killed by decapitation 24 h after the last behav-
ioral session. The hippocampus and prefrontal cortex
were dissected and stored at 80°C. Tissue was homoge-
nized at 4°C in 0.1% Standard Deviation Score (SDS)-
lysis buffer containing 1 mmol/L of a cocktail of protease
inhibitors (Sigma, Milan, Italy), pH 7.4. Homogenates
were centrifuged at 13,000g at 4°C for 20 min and the
supernatant was used for protein determinations. About
30 lg of proteins were resuspended in SDS-bromophenol
blue reducing buffer containing 40-mmol/L dithiothreitol
and separated by electrophoresis on 12% SDS poly-
acrylamide gels, and later transferred to nitrocellulose
membranes (Bio-Rad, Segrate, Milan, Italy). Transfer
was performed at 4°C for 2 h in a buffer containing
25 mmol/L TRIS (Tris (hydroxymethyl) aminomethane),
192 mmol/L glycine, and 20% methanol, at 360 mA. Fil-
ters were blocked 10 min at 4°C in TBST= TBS Tween
buffer containing 10% nonfat dry milk and then incu-
bated with gentle shaking with the following primary
antibodies: anti-BDNF (N-20) (rabbit polyclonal, 1:800,
overnight at 4°C; Santa Cruz Biotechnology), anti-
HDAC2 (mouse monoclonal, 1:5000, overnight at 4°C;
Abcam, Cambridge, UK), anti-H3K14Ac (rabbit poly-
clonal, 1:1000, overnight, Upstate), and anti-b-Actin
(mouse monoclonal, 0.5 lg mL1, 1 h at RT; Sigma-
Aldrich). After three washes with TTBS buffer, blots were
incubated for 1 h at room temperature with peroxydase-
conjugated secondary anti-rabbit or anti-mouse antibod-
ies (Sigma-Aldrich). Immunostaining was revealed by
enhanced chemiluminescence (Amersham Biosciences,
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Milan, Italy). Densitometric analysis was performed with
Quantity One software (Bio-Rad).
RNA isolation, reverse transcription and
quantitative real-time PCR
Total RNA was isolated from tissues using TRIzol reagent
(Invitrogen, Monza MB, Italy) according to the manufac-
turer’s protocol, and retrotranscribed into cDNA by using
SuperScript III Reverse Transcriptase (Invitrogen). Real-
time RT-PCR was performed on a Step One Plus Applied
Biosystems. PCR was performed by using Power SYBR
Green PCR Master Mix Kit (Applied Biosystems, Monza
MB, Italy) according to the manufacturer’s instructions.
Thermal cycler conditions were as follows: 10 min at
95°C, 40 cycles of denaturation (30 sec at 95°C), and
combined annealing/extension (1 min at 58°C). The fol-
lowing primers were used: Total Bdnf: forward 50-CAG-
GTTCGAGAGGTCTGACGA-30 and reverse 50-
CGCGTCCTTATGGTTTTCTTCG-30; Hdac2: forward 50-
GGGACAGGCTTGGTTGTTTC-30 and reverse 50- GAG
CATCAGCAATGGCAAGT-30; Gapdh: forward 50-CGTC
CCGTAGACAAAATGGT-30 and reverse 50-TCAATGA
AGGGGTCGTTGAT -30. The amount of mRNA was cal-
culated from serially diluted standard curves simulta-
neously amplified with the samples and normalized with
respect to Gapdh mRNA levels.
Statistical analysis
Statistical analysis was performed by Student’s t-test
(Figs. 1B, D, G, and 7B, D, E), one-way anaylsis of vari-
ance (ANOVA) + Tukey’s t-test (Figs. 1F, 2G, 3A, and
B), or two-way ANOVA + Fisher’s LSD (Figs. 2A, C, E,
F, 4C, 5A, B, and 6A, B).
Results
Effect of fingolimod treatment on CUS-
induced depressive-like behaviour and
depression-related biochemical changes in
the hippocampus and prefrontal cortex
Antidepressant-like activity of fingolimod in mice
exposed to CUS
The effect of CUS on depressive-like behavior was exam-
ined using the FST and SPT. The two tests were per-
formed with 1 h of interval prior to the onset of CUS,
and then after 3 weeks of CUS. At 3 weeks, CUS
increased the immobility time in the FST in 66% of mice,
whereas it reduced sucrose preference only in 30% of
mice. There was only a partial overlapping between the
groups of responsive mice in the two tests. Hence, we
only used the FST for the assessment of the antidepres-
sant-like activity of fingolimod. Mice showing a reduced
immobility time after 3 weeks of CUS were treated i.p.
with saline or fingolimod (3 mg kg1) once a day for
28 days. Unstressed mice were also treated with saline or
fingolimod for 4 weeks (Fig. 1A).
Three weeks of CUS significantly increased the immo-
bility time as compared to baseline values (Fig. 1B). We
arbitrarily considered CUS-exposed mice as “non-resil-
ient” to stress if they showed at least + 1 SDS in the vari-
ation of the immobility time at 3 weeks, with respect to
the mean variation in unstressed mice. Twenty-five of the
38 mice exposed to CUS were classified as “non-resilient”
to stress and used for further analysis (Fig. 1C).
Treatment with saline for 4 weeks further increased the
immobility time in stressed mice, perhaps because of the
additional exposure to CUS during the first week of treat-
ment. This increase was significantly reduced in mice trea-
ted with fingolimod (Fig. 1D). Although the overall effect
of fingolimod was statistically significant, the drug was
not effective in all CUS mice. At the end of treatment,
nine of the 13 mice treated with fingolimod showed a
reduction in the immobility time < 1 SDS with respect
to the mean of saline-treated mice and were considered as
“drug-responders.” The four mice with a reduction in the
immobility time < 1 SDS were classified as nonrespond-
ers (Fig. 1E). Absolute values are reported in Figure 1F,
which shows a significant reduction in the immobility
time only in the group of responder mice. The effect of
fingolimod was still significant when data of responders
and nonresponders were combined and compared to data
obtained in mice treated with saline (Fig. 1G). Treatments
with saline or fingolimod had no effect on the immobility
time in unstressed mice (not shown).
CUS-induced changes in the expression of BDNF
and HDAC2 in the hippocampus were corrected
by fingolimod
As biochemical correlates with depressive-like behavior,
we measured BDNF and HDAC2 mRNA and protein lev-
els, and H3 histone acetylation in the hippocampus.
BDNF and HDAC2 were also measured in the prefrontal
cortex.
Stressed mice treated with saline showed a large reduc-
tion in hippocampal BDNF protein levels, as compared to
unstressed mice treated with saline. Treatment with fingo-
limod reversed the effect of CUS on BDNF levels exclu-
sively in mice that responded to the drug in the FST
(Fig. 2A). Fingolimod did not change hippocampal BDNF
levels in unstressed mice (Fig. 2A). Linear regression
analysis showed a significant negative correlation between
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BDNF levels and the immobility time in the FST
(r = 0.72; P < 0.05) (Fig. 2B). Specular data were
obtained with measurements of HDAC2 protein levels in
the hippocampus. CUS caused a significant increase in
HDAC2 levels, which was reversed by fingolimod only in
“responder” mice. Fingolimod had no effect on HDAC2
levels in unstressed mice (Fig 2C). A positive correlation
was found between HDAC2 levels and the immobility
time (r = 0.77; P < 0.05) (Fig. 2D). Data of BDNF and
HDAC2 mRNA levels in CUS mice paralleled data of pro-
tein levels, with fingolimod reversing the effect of stress
in responder mice. In unstressed mice, fingolimod caused
a significant reduction in BDNF mRNA levels (Fig. 2E),
although it did not change BDNF protein levels (Fig. 2A).
Fingolimod had no effect on HDAC2 mRNA levels in
unstressed mice (Fig. 2F). We also measured H3K14Ac in
(A) (B)
(C)
(E) (F) (G)
(D)
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the hippocampus of CUS mice. Fingolimod treatment
enhanced H3K14Ac levels only in “responder” mice
(Fig. 2G).
In the prefrontal cortex, exposure to CUS significantly
reduced BDNF protein levels but did not cause significant
changes in HDAC2 protein levels. Mice treated with
Stressed
BDNF
β-Actin
HDAC2
(A) (B)
Sa
lin
e
14 kDa
55 kDa
14 kDa
55 kDa
Saline
BDNF
β-Actin
HDAC2
Figure 3. Fingolimod treatment did not cause significant changes in cortical BDNF and HDAC2 levels in stressed mice classified as “drug
responders.” BDNF and HDAC2 levels in the prefrontal cortex of unstressed and CUS (stressed) mice treated with saline or fingolimod are shown
in (A) and (B), respectively. Values are means + SEM. In (A), n = 9 and 4 in unstressed mice treated with saline and fingolimod, respectively;
n = 8 in mice treated with saline and fingolimod (four responders and 4 nonresponders). In (B), n = 7 and 3 in unstressed mice treated with
saline and fingolimod, respectively; n = 8 and 11 in mice treated with saline and fingolimod, respectively (seven responders and four
nonresponders to fingolimod). Two-way ANOVA + Fisher’s LSD; BDNF levels, stress/no stress: F(1,24) = 9.96, P < 0.05; drug treatment:
F(1,24) = 2.445, P > 0.05; HDAC2 levels, stress/no stress: F(1,24) = 2.77, P > 0.05; drug treatment: F(3,24) = 0.06, P > 0.05). Post hoc analysis:
*P < 0.05 versus the respective values obtained in unstressed mice treated with saline.
Figure 2. Fingolimod treatment corrects biochemical changes caused by CUS in the mouse hippocampus. The effect of CUS and/or fingolimod
on BDNF protein levels in the hippocampus is shown in (A). Densitometric values are means + SEM n = 7 and 6 for unstressed mice treated with
saline and fingolimod, respectively; n = 8 and 13 for CUS (stressed) mice treated with saline and fingolimod, respectively. Stressed mice treated
with fingolimod were subdivided into responders and nonresponders (n = 9 and 4, respectively). Two-way ANOVA + Fisher’s LSD; stressed/
unstressed: F(1,29) = 10.12; drug treatment: F(3,29) = 9.52; P < 0.05. Post hoc analysis: P < 0.05 versus unstressed mice treated with saline (*) or
versus all other values except values in unstressed mice treated with saline (#). Linear regression analysis of BDNF levels and D values of immobility
time between week 7 and week 3 in CUS mice treated with fingolimod (n = 13) is shown in (B). The effect of CUS and/or fingolimod on HDAC2
protein levels in the hippocampus is shown in (C). Densitometric values are means + SEM n = 7 and 4 for unstressed mice treated with saline and
fingolimod, respectively; n = 8 and 9 for stressed mice treated with saline and fingolimod, respectively. Stressed mice treated with fingolimod
were subdivided into responders and nonresponders (n = 5 and 4, respectively). Two-way ANOVA + Fisher’s LSD; stressed/unstressed:
F(1,23) = 11.99, P < 0.05; drug treatment: F(3,23) = 6.39, P < 0.05. Post hoc analysis: P < 0.05 versus unstressed mice treated with saline (*) or
versus stressed mice treated with saline and nonresponders to fingolimod (#). Linear regression analysis of HDAC2 levels and D values of
immobility time between week 7 and week 3 in CUS mice treated with fingolimod (n = 13) is shown in (D). The effect of CUS and/or fingolimod
on BDNF and HDAC2 mRNA levels in the hippocampus is shown in (E) and (F), respectively. Values are means + SEM of 3–4 determinations in (E)
and 2–5 determinations in (F). Two-way ANOVA + Fisher’s LSD; BDNF mRNA levels, stressed/unstressed: F(1,11) = 30.063, P < 0.05; drug
treatment: F(1,11) = 0.805, P > 0.05; stressed/unstressed x drug treatment: F(1,11) = 25.849, P < 0.05; HDAC2 mRNA levels, stressed/unstressed:
F(1,10) = 3.141, P > 0.05; drug treatment: F(1,10) = 3.529, P > 0.05; stressed/unstressed x drug treatment: F(1,10) = 19.368, P < 0.05. Post-hoc
analysis: P < 0.05 versus the respective unstressed mice treated with saline (*) or the respective stressed mice treated with saline (#).H3K14 Ac
levels in the hippocampus of CUS mice treated with saline or fingolimod (divided into responders and nonresponders) are show in (G), where
data are means + SEM of 2–3 determinations (SD is reported for the saline group in which n = 2). One-way ANOVA + Tukey’s t-test;
F(2,5) = 11.09; P < 0.05. Post hoc analysis: *P < 0.05 versus all other values.
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Figure 4. Fingolimod treatment had no effect on anxiety-like behavior in the EPM or spatial learning in the 1 day Morris water maze. The design
of experiment #2 is show in (A). Single values at the EPM are shown in (B). Values (means + SEM) of the three blocks of trials in the water maze
are shown in (C). n = 8 and 11 for unstressed mice treated with saline and fingolimod, respectively; n = 8 and 12 for stressed mice treated with
saline and fingolimod, respectively. Two-way ANOVA for repeated measures showed a significant difference among the blocks (F2,36 = 7.54;
P < 0.05), a significant effect of CUS (F1,36 = 13.44; P < 0.05), and no effect of treatment (F1,36 = 0.048; P > 0.05) or CUS 9 treatment
(F1,36 = 2.14; P > 0.05). Single values of the probe test (the time spent in the quarter of the maze previously associated with the platform) are
shown in (D). EPM, elevated plus maze; MWM, morris water maze; SI, social interaction test.
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fingolimod showed a trend to an increase in BDNF levels,
with no difference between responders and nonresponders
(Fig. 3A). The drug had no effect on cortical HDAC2
levels (Fig. 3B).
Effect of CUS and fingolimod treatment on EPM,
spatial learning, social interaction, and
hippocampal neurogenesis
The second set of mice subjected to CUS and treated as
above underwent behavioral analysis in the EPM, social
interaction test, and 1 day MWM test, and were also used
for the assessment of neurogenesis in the hippocampal
dentate gyrus (see Fig. 4A).
Fingolimod had no effect on anxiety-like
behaviour in the EPM or spatial learning in the
1 day water maze
The EPM test was performed twice, prior to the onset of
CUS and 24 h after the last injection of saline or fingoli-
mod. We found no effects of CUS or fingolimod treatment
in the EPM test, as reflected by the time spent by each
mouse in the open and closed arms of the EPM (Fig. 4B).
Spatial learning was assessed by 1 day MWM performed
3 days following the last EPM test. Mice were subjected to
three blocks of three trials separated by a 30-min interval.
Data from the three blocks of trials (Fig. 4C) and the probe
test (Fig. 4D) showed no effect of fingolimod on spatial
learning in both unstressed and CUS mice.
Fingolimod treatment mimicked and occluded the
effect of CUS on social interaction
The social interaction test can be used as a test of anxi-
ety-like behavior from an ethological perspective (File and
Hyde 1978). Data from the SR phase of the test are
shown in Fig. 5. Both CUS and fingolimod increased the
time spent in proximity of the familiar conspecific
(Fig. 5A), and reduced the time spent in proximity of the
novel conspecific (Fig. 5B). CUS and fingolimod treat-
ment were mutually occlusive in the social interaction test
(Fig. 5A and B).
Fingolimod treatment reversed the reduction of
adult hippocampal neurogenesis induced by CUS
At the end of the last behavioral session all mice were
treated with BrdU and killed after 2 days (corresponding
to day 12 after the end of treatments with saline or fingo-
limod) for the assessment of hippocampal neurogenesis.
Exposure to CUS reduced the absolute number of prolif-
erating progenitors in the dentate gyrus, as assessed by
stereological counting of BrdU+ cells. The effect of CUS
was reversed by fingolimod (Fig. 6A). Similar data were
obtained by measuring the number of cells expressing
DCX, a microtubule-associated protein specifically found
in neuronal precursor cells and immature neurons (von
Bohlen and Halbach 2011) (Fig. 6B).
Effect of fingolimod on corticosterone-
induced depressive-like behaviour
After 21 days of treatment with corticosterone (or vehi-
cle), the depressive-like behavior of mice was assessed
Interaction with novel animal
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Figure 5. Fingolimod treatment mimicked and occluded the action of
CUS in the social interaction test. Values of the recognition phase of test
relative to the interaction with the familiar and the novel conspecific are
shown in (A) and (B), respectively. Values are means + SEM n = 7 and
11 for unstressed mice treated with saline or fingolimod, respectively;
n = 7 and 12 for CUS (stressed) mice treated with saline and fingolimod,
respectively. Two-way ANOVA + Fisher’s LSD; time spent with the
familiar conspecific, stressed/unstressed: F3,33 = 6.63, P < 0.05; drug
treatment: F3,33 = 1.205, P > 0.05; stressed/unstressed 9 drug
treatment, F3,33 = 7.64, P < 0.05; time spent with the novel conspecific,
stressed/unstressed: F3,33 = 3.96, P > 0.05; drug treatment: F3,33 =
3.71, P > 0.05; stressed/unstressed 9 drug treatment, F3,33 = 5.82,
P < 0.05. Post hoc analysis: *P < 0.05 versus the respective values
obtained in unstressed mice treated with saline.
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using the FST and the SPT, as described above. Com-
pared to baseline values, corticosterone treatment
increased the time spent in immobility in the FST
(Fig. 7B) in 77% of mice (17 out of 22). We arbitrarily
considered as “Responders to corticosterone” mice that
showed at least +0.20 SDS in the variation of immobility
time at 3 weeks, with respect to the mean variation in
vehicle-treated mice (Fig. 7C).
Responders to corticosterone were then treated with
fingolimod (3 mg kg1) or saline for 4 weeks. Fingolimod
induced a significant reduction in the time spent in
immobility, with respect to values obtained at 3 weeks
(Fig. 7D). Fingolimod also significantly reduced the
immobility time when compared to saline (Fig. 7E).
Treatment with corticosterone and fingolimod had
no appreciable effects on the hedonic component of
depressive-like behavior, as assessed with the SPT (data
not shown).
Discussion
Our data show an antidepressant-like activity of fingoli-
mod in mice exposed to CUS and in mice chronically
treated with corticosterone. Stress-based models of
depression, including the CUS model, have face validity
and are highly responsive to antidepressant medication
(Nestler and Hyman 2010; Krishnan and Nestler 2011).
The corticosterone model mimics the dysfunction of
the hypothalamic–pituitary–adrenal (HPA) axis associ-
ated with major depression, and recapitulates some of
the hallmark symptoms of depression (reviewed by
Gourley and Taylor 2009). As opposed to the CUS
model, the corticosterone model, under our experimen-
tal conditions, is refractory to classical antidepressants
(Iijima et al. 2010; Ago et al. 2013). Fingolimod treat-
ment was effective in both models in relieving depres-
sive-like behavior in the FST. The two models,
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Figure 6. Fingolimod treatment enhances adult neurogenesis in the hippocampal dentate gyrus of mice exposed to CUS. Stereological counts of
BrdU+ or DCX+ cells in the dentate gyrus of unstressed and CUS (stressed) mice treated with saline or fingolimod are reported in (A) and (B),
respectively. Representative images of BrdU or DCX staining are also shown. Values are means + SEM of 5 determinations per group in (A) and 4
determinations per group in (B). Two-way ANOVA + Fisher’ LSD; BrdU+ cells, stressed/unstressed: F(3,16) = 3.829, P > 0.05; drug treatment:
F(3,16) = 4.366, P > 0.05; stressed/unstressed x drug treatment: F(3,16) = 5.273, P < 0.05; DCX
+ cells, stressed/unstressed: F(3,12) = 2.483, P > 0.05;
drug treatment: F(3,12) = 20.898, P < 0.05; stressed/unstressed 9 drug treatment: F(3,12) = 6.768, P < 0.05. Post hoc analysis: P < 0.05 versus the
respective groups of unstressed mice treated with saline (*), or versus the respective groups of stressed mice treated with saline (#).
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however, did not allow the examination of the effect
fingolimod on anhedonia. Mice treated with corticoste-
rone for 3 weeks did not show the expected reduction
in sucrose preference (Gourley and Taylor 2009), and
only a small percentage of mice exposed to CUS
showed anhedonia in the SPT. This was unexpected
because inhibition of sucrose preference has been
reported in C57/BL mice exposed to unpredictable
chronic mild stress (Pothion et al. 2004; Cuccurazzu
et al. 2013; but see also Farley et al. 2012 for contrast-
ing results). Further studies with other animal models
are required for the evaluation of the activity of fingo-
limod on anhedonic behavior.
A 4 week treatment with fingolimod in “non-resilient”
CUS mice caused antidepressant-like effect in the FST.
However, about 30% of CUS mice did not respond to
fingolimod for unknown reasons. Interestingly, fingoli-
mod corrected the abnormalities in BDNF levels, HDAC2
levels, and H3K14 acetylation in the hippocampus only in
those mice that were classified as “responders” on the
basis of behavioral data. This correlation was not found
in the prefrontal cortex of CUS mice, where fingolimod
(A)
(B) (C)
(D) (E)
Figure 7. Antidepressant-like activity of fingolimod in mice chronically treated with corticosterone The design of the experiment is shown in (A).
Mice were treated systemically with corticosterone (20 mg kg1, s.c.) or vehicle (Ctrl) for 3 weeks, tested for depressive-like behavior in the
forced swim test (FST) and sucrose preference test (SPT), and then treated i.p. once daily for 4 weeks with either saline (both groups) or
fingolimod (3 mg kg1, only the corticosterone group). All data of the FST in Ctrl mice and in mice treated with corticosterone (n = 11 and 22,
respectively) are shown in B, where data (means + SEM) are expressed as the difference of immobility time (D) between values obtained at week
3 and time 0. *P < 0.05 (Student’s t-test; t(31) = 2.14) versus unstressed mice. Mice responders (n = 17) and nonresponders (n = 6) to
corticosterone are shown in (C), where the cutoff value for resilience was considered <0.20 Standard Deviation Score (SDS) with respect to the
mean value of immobility time in control mice treated with vehicle. The effect of fingolimod on the immobility time in the FST is shown in (D),
where data (means + SEM) are expressed as the difference of immobility time (D) between values obtained at week 7 and week 3. *P < 0.05
(Student’s t-test; t(15) = 2.33) versus mice treated with saline (n = 7 in both groups). Absolute values of immobility time (means + SEM) in mice
treated with saline or fingolimod are shown in (E). *P = 0.05 (Student’s t test; t15 = 2.09) versus saline.
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caused a trend to an increase in BDNF levels in both
responders and nonresponders, and had no effect on
HDAC2 levels. These findings suggest that fingolimod acts
primarily in the hippocampus through an epigenetic
mechanism that causes an enhanced production of BDNF,
resulting in an antidepressant-like effect (see Introduction
and References therein).
To the best of our knowledge, our data offer the first
demonstration that hippocampal HDAC2 levels are
increased in a model of chronic stress. This contrasts with
the reduced HDAC2 mRNA levels found in the hippo-
campus of mice exposed to restraint stress for 14 days
(Han et al. 2014). Changes in hippocampal HDAC2 levels
found in response to CUS and fingolimod were comple-
mentary to changes in BDNF levels, in line with the evi-
dence that HDAC2 epigenetically downregulates BDNF
expression (Gr€aff et al. 2012). The ability of fingolimod
to enhance H3K14Ac levels in CUS mice is fully consis-
tent with its putative antidepressant activity because
chronic social defeat stress – another validated stress-
based model of depression – causes a persistent reduction
in hippocampal H3K14Ac levels, which is reversed by
imipramine treatment (Covington et al. 2011). Interest-
ingly, acetylation of another H3 lysine residue (H3K9) is
enhanced by a 3-day treatment with fingolimod in severe
combined immunodeficiency disorder (SCID) mutant mice
subjected to a contextual fear extinction test (Hait et al.
2014), suggesting that the drug may activate different epi-
genetic mechanisms depending on the context, length of
treatment, and strain of mice.
Another finding that supports the antidepressant-like
activity of fingolimod was the enhancing effect of the
drug on hippocampal neurogenesis in CUS mice. Adult
hippocampal neurogenesis is negatively regulated by
chronic stress, and an increased neurogenesis contributes
to some (but not all) “therapeutic” effects of antidepres-
sant drugs (Santarelli et al. 2003; David et al. 2009; Hsieh
and Eisch 2010; Hanson et al. 2011). Because of the com-
plex design of experiment #2, hippocampal neurogenesis
was assessed 12 days after the end of drug treatment. This
suggests that fingolimod produces long-lasting effects (at
least on hippocampal neurogenesis), which might depend
either on the long half-life of the drug (>60 h) or to the
enduring consequences of histone acetylation (see above).
In the same groups of mice used for the assessment of
neurogenesis, we examined the effect of CUS and fingoli-
mod on EPM, one-day water maze, and social interaction.
Under our conditions, fingolimod had no effect on anxi-
ety-like behavior in the EPM and spatial learning in the
water maze. It should be highlighted that, under our
experimental conditions, CUS did no cause changes in
anxiety-like behavior or spatial learning. Thus, our data
do not exclude an action of fingolimod on anxiety and
cognitive dysfunction associated with depression. In con-
trast, fingolimod mimicked and occluded the action of
CUS in reducing the time spent in proximity of a novel
animal in the recognition phase of the social interaction
test. This particular effect of fingolimod might reflect an
increased level of anxiety caused by the novel animal (File
and Hyde 1978), but might also be secondary to an
increased affiliative behavior toward the familiar animal.
Hait et al. (2014) have shown that a 3-day treatment with
fingolimod enhances the extinction of fear memory in
SCID mutant mice. SCID mice represent an elegant
model for the study of the central action of fingolimod
without the influence of peripheral immune suppression,
but are not an optimal model for the study of depression-
and anxiety-like behavior because immune deficiency has
a profound impact on the activity of the HPA axis. All
together, these findings suggest that the effect of fingoli-
mod on anxiety-like behavior is complex and requires
further investigation.
Fingolimod is transformed inside the cell into fingoli-
mod-P, which may interact with membrane S1PRs via
an “inside-out” mechanism (Brinkmann et al. 2010), or,
alternatively, inhibit class-I HDACs in the cell nucleus
(Hait et al. 2014). Both mechanisms might contribute to
the antidepressant-like activity of fingolimod and the
associated increase in hippocampal BDNF levels and
neurogenesis. The use of subtype-selective S1PR antago-
nists or conditional null mice lacking S1P1Rs in specific
CNS cell lineages (Choi et al. 2011) is needed to exam-
ine the role of S1PRs in the antidepressant effect of fin-
golimod. At least under our conditions, fingolimod had
no effect on depressive-like behavior, BDNF protein lev-
els, HDAC2 mRNA and protein levels, and adult neuro-
genesis in unstressed control mice. A “disease-
dependent” effect is also reported in a mouse model of
Alzheimer’s disease, in which peripheral administration
of fingolimod for two weeks reversed the reduction in
hippocampal BDNF levels caused by i.c.v. infusion of
full-length b-amyloid peptide, with no effect on BDNF
levels in control mice (Fukumoto et al. 2014). In their
seminal manuscript, Deogracias et al. (2012) have shown
that a single injection of fingolimod enhances hippocam-
pal BDNF mRNA and protein levels in normal mice. In
our unstressed control mice, chronic treatment with fin-
golimod caused no changes in BDNF protein levels and
even a significant reduction in BDNF mRNA levels in
the hippocampus. Perhaps tolerance develops to the
BDNF-enhancing effect of fingolimod after repeated
injections of the drug unless BDNF levels are pathologi-
cally reduced, as occurs in CUS mice (present data), in
mice injected with b-amyloid peptide (Fukumoto et al.
2014), or in mutant mice modeling Rett’s syndrome
(Deogracias et al. 2012).
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In conclusion, our findings raise the interesting possi-
bility that fingolimod relieves depressive symptoms in MS
patients independently of its established disease-modifying
activity (Aktas et al. 2010; Brinkmann et al. 2010; Pelle-
tier and Hafler 2012; Comi 2013; di Nuzzo et al. 2014).
Post hoc data from the phase 4 EPOC trial (Clinical Tri-
als.gov, identifier NCT01216072) presented as a poster at
the 29th Congress of the European Committee for Treat-
ment and Research in MS (Hunter et al. 2013) show that
a larger proportion of MS patients who were depressed at
baseline were no longer depressed 6 months after switch-
ing the therapy from IFN-b or glatiramer acetate (GA)
into fingolimod with respect to patients who switched
from IFN-b into GA or vice versa (50.5% vs. 25.3%).
This encourages the design of controlled clinical trials in
which the antidepressant activity of fingolimod is com-
pared to the activity of drugs endowed with high thera-
peutic efficacy in MS patients, such as natalizumab.
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